Literature DB >> 6815296

Measuring the benefits of screening for open neural tube defects.

J B Henderson.   

Abstract

Evaluation of the costs and benefits of public sector programmes is necessary to plan the optimum uses for society's resources. Here the benefits of screening for open neural tube defects are examined, and the most appropriate methodological approach to their valuation is discussed in the context of the possible provision by the National Health Service of a routine prenatal screening programme. It is argued that, in measuring the benefits of screening, previous evaluations have adopted an approach that is rather unsatisfactory from the standpoint of economic methodology. An attempt is therefore made here to show the effect that adopting a more appropriate approach would have on the estimated value of the benefit of routine screening. The effect is found to be a substantial increase in its estimated value.

Entities:  

Mesh:

Year:  1982        PMID: 6815296      PMCID: PMC1052214          DOI: 10.1136/jech.36.3.214

Source DB:  PubMed          Journal:  J Epidemiol Community Health        ISSN: 0143-005X            Impact factor:   3.710


  18 in total

1.  Handicap and social status of adults with spina bifida cystica.

Authors:  K Evans; V Hickman; C O Carter
Journal:  Br J Prev Soc Med       Date:  1974-05

2.  Spina bifida and anencephalus in greater London.

Authors:  C O Carter; K Evans
Journal:  J Med Genet       Date:  1973-09       Impact factor: 6.318

3.  A genetic study of anencephaly and spina bifida in Glasgow.

Authors:  I D Richards; H T McIntosh; S Sweenie
Journal:  Dev Med Child Neurol       Date:  1972-10       Impact factor: 5.449

4.  The cost-benefit approach.

Authors:  A Williams
Journal:  Br Med Bull       Date:  1974-09       Impact factor: 4.291

5.  Fetal malformations and abnormalities.

Authors:  K M Laurence
Journal:  Lancet       Date:  1974-10-19       Impact factor: 79.321

6.  Spina bifida--and the parents.

Authors:  J H Walker; M Thomas; I T Russell
Journal:  Dev Med Child Neurol       Date:  1971-08       Impact factor: 5.449

7.  A family study of major central nervous system malformations in South Wales.

Authors:  C O Carter; P A David; K M Laurence
Journal:  J Med Genet       Date:  1968-06       Impact factor: 6.318

8.  Screening for spina bifida cystica. A cost-benefit analysis.

Authors:  S Hagard; F Carter; R G Milne
Journal:  Br J Prev Soc Med       Date:  1976-03

9.  The effectiveness of genetic counselling for neural-tube malformations.

Authors:  J Morris; K M Laurence
Journal:  Dev Med Child Neurol Suppl       Date:  1976

10.  Preventing the birth of infants with Down's syndrome: a cost-benefit analysis.

Authors:  S Hagard; F A Carter
Journal:  Br Med J       Date:  1976-03-27
View more
  6 in total

1.  Services for thalassaemia as a model for cost-benefit analysis of genetics services.

Authors:  B Modell; A M Kuliev
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

2.  When does mass screening for open neural tube defects in low-risk pregnancies result in cost savings?

Authors:  L L Tosi; A S Detsky; D P Roye; M L Morden
Journal:  CMAJ       Date:  1987-02-01       Impact factor: 8.262

3.  The distinction between worth and affordability: implications of costs and benefits for the allocation of health care resources.

Authors:  M C Charny; C J Roberts
Journal:  Postgrad Med J       Date:  1986-12       Impact factor: 2.401

4.  Valuation of life in long run health care programmes.

Authors:  R R West
Journal:  Br Med J (Clin Res Ed)       Date:  1985-10-19

5.  Surgical treatment of myelomeningocele: year 2000 hospitalization, outcome, and cost analysis in the US.

Authors:  Anthony H Sin; Mahmoud Rashidi; Gloria Caldito; Anil Nanda
Journal:  Childs Nerv Syst       Date:  2007-06-06       Impact factor: 1.475

6.  Prenatal screening for cystic fibrosis carriers: an economic evaluation.

Authors:  P T Rowley; S Loader; R M Kaplan
Journal:  Am J Hum Genet       Date:  1998-10       Impact factor: 11.025

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.